Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 8/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TACR1 | P25103 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL534386 | 0.92 | OPRK1 (0.33) | OPRK1OPRD1RENKCNH2TACR1 | |
| SCHEMBL534387 | 0.92 | OPRK1 (0.33) | OPRK1OPRD1RENKCNH2TACR1 | |
| SCHEMBL535215 | 0.90 | TACR1 (0.39) | TACR1 | |
| SCHEMBL556773 | 0.88 | OPRK1 (0.38) | OPRK1OPRD1RENKCNH2TACR1 | |
| SCHEMBL534508 | 0.86 | MEN1 (0.37) | OPRK1OPRD1OPRM1 | |
| SCHEMBL534235 | 0.85 | OPRK1 (0.35) | OPRK1OPRD1RENKCNH2TACR1 | |
| SCHEMBL556826 | 0.78 | MEN1 (0.36) | OPRK1OPRD1OPRM1 | |
| SCHEMBL556825 | 0.78 | MEN1 (0.36) | OPRK1OPRD1OPRM1 | |
| SCHEMBL534595 | 0.73 | OPRK1 (0.40) | OPRK1OPRD1OPRM1 | |
| SCHEMBL555641 | 0.73 | TACR1 (0.37) | RENKCNH2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | OPRK1 980/4885OPRD1 1410/4885REN 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.